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a b s t r a c t
Background: Full genome sequencing of inﬂuenza A viruses (IAV), including those that arise from annual
inﬂuenza epidemics, is undertaken to determine if reassorting has occurred or if other pathogenic
traits are present. Traditionally IAV sequencing has been biased toward the major surface glycoproteins
haemagglutinin and neuraminidase, while the internal genes are often ignored. Despite the develop-
ment of next generation sequencing (NGS), many laboratories are still reliant on conventional Sanger
sequencing to sequence IAV.
Objectives: To develop a minimal and robust set of primers for Sanger sequencing of the full genome of
IAV currently circulating in humans.
Study design: A set of 13 primer pairs was designed that enabled ampliﬁcation of the six internal genes
of multiple human IAV subtypes including the recent avian inﬂuenza A(H7N9) virus from China. Speciﬁc
primers were designed to amplify the HA and NA genes of each IAV subtype of interest. Each of the
primers also incorporated a binding site at its 5′-end for either a forward or reverse M13 primer, such
that only two M13 primers were required for all subsequent sequencing reactions.
Results: This minimal set of primers was suitable for sequencing the six internal genes of all currently
circulating human seasonal inﬂuenza A subtypes as well as the avian A(H7N9) viruses that have infected
humans in China.
Conclusions:This streamlinedSanger sequencingprotocol couldbeused togenerate full genomesequence
data more rapidly and easily than existing inﬂuenza genome sequencing protocols.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Background
Inﬂuenza viruses belong to the family of Orthomyxoviridae RNA
viruses. Inﬂuenza A viruses (IAV) contain eight segmented nega-
tive strand RNAs of approximately 13.5 kbwhich encode at least 12
proteins, including polymerase basic protein 2 (PB2) and 1 (PB1),
PB1-F2, polymerase acidic protein (PA) and PA-X, hemagglutinin
(HA), nucleoprotein (NP), neuraminidase (NA),matrixprotein1and
2 (M1 and M2), and non-structural protein 1 and 2 (NS1 and NS2)
[1]. There are 18 types of HA and 11 types of NA [2–5], and the
combination of HA and NA subtypes provides the basis for IAV sub-
type classiﬁcation (such as H1N1 and H3N2). Most of the subtypes
are found in avian, some in swine, human and other species such
∗ Corresponding author. Tel.: +61 3 93429312; fax: +61 3 93429129.
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as bats. While H1N1 and H3N2 are the most common subtypes
currently circulating in humans [6], there have also been sporadic
cases of human infection with other inﬂuenza A subtypes in recent
years [7], such as H5N1,H7N9, H10N7, H7N9 and H9N2, H6N1
[8–15].
Both the HA and NA genes of inﬂuenza A, particularly those
present in the currently circulating humanH1N1 andH3N2 viruses
continually evolve due to immune pressure from previous infec-
tions, leading to antigenic drift in the virus. In contrast, the six
internal genes are relatively stable, although genetic reassortment
among different virus subtypes can occur within avian and swine
hosts, and less frequently in thehumans. Fromtime to time, someof
these reassortant IAV viruses from animal sources may develop an
ability to infect humans, such as was seen with the 2009 pandemic
H1N1 virus, which appears to have been a swine reassortant virus
[16]. Full genome sequencing of IAV is the standard way to iden-
tify the origin of a newly reassortant virus and it is also a powerful
tool to help elucidate themolecular characteristics of the virus such
http://dx.doi.org/10.1016/j.jcv.2015.04.019
1386-6532/© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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as host range, replication efﬁciency, transmissibility and virulence
[17–20].
There are two main technologies that are currently in use
for inﬂuenza full genome sequencing, namely the next gener-
ation sequencing (NGS) and traditional Sanger sequencing. The
entire genome sequences regardless of the subtypes can be ampli-
ﬁed using universal IAV primers, and then sequenced using NGS
[21–23], however, the cost and availability of NGS equipment, cou-
pled with the need for complicated bioinformatics analysis, are
major barriers for many laboratories to introduce this new tech-
nology. Therefore, Sanger sequencing is still widely used inmost of
the laboratories involved in inﬂuenza surveillance and research.
2. Objectives
To develop a simple Sanger sequencing method that is able to
amplify and sequence the full genomes of multiple circulating sea-
sonal human IAV subtypes using theminimum number of primers.
3. Study design
3.1. Primer design
Sequence data for all eight genes of A(H3N2), A(H1N1),
A(H1N1pdm09) were downloaded from the global initiative on
sharing avian inﬂuenza data (GISAID) website, alignment of indi-
vidual genes was done in Geneious 5.1 (Biomatters Ltd-New
Zealand). HA and NA primers were designed speciﬁc for each IAV
subtype unless otherwise stated. Primers for the internal gene
segments were designed at a minimum to cover all known IVAs
belonging to the seasonal H1N1, H3N2 and H1N1pdm09. All genes
except the Matrix gene and NS gene (where only single sets of
primers were used) were ampliﬁed with 2–3 overlapping PCR seg-
ments to ensure that good quality sequence data could be obtained
from both directions in one segment, all primers were each tagged
with either M13F or M13R universal sequencing primer at the 5′
end, so that only two primers (M13F and M13R) were needed for
sequencing all the PCR products (Fig. 1). Altogether, 17 pairs of
primers were needed to amplify the whole inﬂuenza A genome of
each subtype of IAVs, of which 13 pairswere universal primers that
could amplify the six internal gene segments of all known IAVs cur-
rently circulating in humans (Table 1). Some of the primers were
used were those recommended by the US CDC (Atlanta, Georgia)
protocol as indicated in Table 1.
3.2. Virus samples
Samples were received at the WHO Collaborating Centre for
Reference and Research on Inﬂuenza, Melbourne as either IAV iso-
lates in Madin–Darby canine kidney (MDCK ATCC CCL-34) cells
or original respiratory clinical specimens (e.g. nasal swabs, throat
swabs, nasal aspirates, nasopharyngeal swabs) fromWHONational
Inﬂuenza Centres, and other regional laboratories and hospitals in
Australia, New Zealand, and the Asia/Paciﬁc regions. If required
virus samples were cultured in MDCK cells or embryonated hens
eggs as previously described [24,25].
3.3. RNA extraction and RT-PCR
RNA was extracted from 140l of a virus culture or an original
specimen using
QIAamp Viral RNA Mini Kit (Qiagen) according to the manufac-
turer’s instruction.
cDNA was made from each RNA sample using ThermoScript
RT-PCR System for First-Strand cDNA Synthesis (Invitrogen), with
Uni12 primer [26], then 2l of the cDNA was ampliﬁed in a 50l
volume using the Platinum Taq DNA High Fidelity Polymerase kit
(Invitrogen) containing speciﬁc gene primers as shown in Table 1
according to the manufacturer’s instructions.
3.4. Sequencing and sequence analysis
RT-PCR products were puriﬁed by ExoSAP-IT (GE Healthcare),
and then subjected to sequencing reactions using either M13F
or M13R primer with Big Dye Terminator Reaction Mix (Applied
Biosystems). The reaction products were puriﬁed by Big Dye XTer-
minator Puriﬁcation Kit (Applied Biosystems) and run on ABI 3500
XL sequencer. Sequencing results were analysed using the DNAS-
TAR Lasergene 9 package.
4. Results
4.1. Validation of IAV internal primers
A total of 13 pairs of primers were designed for the six inter-
nal gene segments (PB1, PB2, PA, NP, M, NS) of IAV as described
in Methods and Materials. These primers were tested on 25 sea-
sonal H1N1, 120H3N2, 130H1N1pdm09 and 10 inﬂuenza B MDCK
grown viruses, with sample dates from 1980 to 2014. The repre-
sentedviruses sequencedare listed inTable2.When testedon these
viruses the primerswere able to produce distinct PCR products that
could be easily sequenced, and they also performed at a similar
efﬁciency when tested on the different inﬂuenza A subtypes tested
(H1N1, H1N1pdm09 and H3N2), with no cross reactivity against
inﬂuenza B viruses. The analytical sensitivity was also determined
on cDNA derived from serially diluted RNA samples, and similar
levels in the limit of detection (LOD) were found for respective
gene segments of various subtypes, ranging from 50 to 50,000
copies/reaction (data not shown). The LOD for NS and NP genes
were the most sensitive (50 copies/reaction), whereas some poly-
merase fragments had a lower sensitivity (50,000 copies/reaction).
4.2. Speciﬁcity and sensitivity of HA and NA primers
The subtype speciﬁc HA and NA primers were tested for speci-
ﬁcity on over 200 seasonal H1N1 viruses (sample dates from
1934 to 2009), 1500H3N2 viruses (sample dates 1976–2014)
and 1500H1N1pdm09 viruses (sample dates 2009–2014). All the
primers tested were speciﬁc for the HA and NA genes of their
corresponding subtypes, with no cross-reaction to the other IAV
subtypesor inﬂuenzaBvirus. TheLODonHAandNA for all subtypes
were found in the range of 500–5000 copies/reaction.
4.3. Evaluation of IAV internal gene primers for ampliﬁcation of
other subtypes
All the internal primers were further tested on a number of
inﬂuenza A subtypes discovered either in humans or animals.
Results revealed that they were able to amplify the inter-
nal genes of all selected inﬂuenza A viruses including H2N2
(A/Singapore/1/1957), H10N7 (A/Chicken/Queensland/1/2012),
H1N2 (A/Brisbane/116/2002 and A/Sydney/12/2003), and the
avian H7N9 virus (A/Anhui/1/2013) (Table 2). When these primers
were tested on selected H9N2 and H5N1 viruses, only the whole
NP, NS andMP genes, but not the three polymerase genes, could be
ampliﬁed successfully. Analysis of the polymerase genes of these
subtypes revealed a high degree of diversity, making it difﬁcult to
design primers that also covered both H5N1 and H9N2 polymerase
genes.
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Fig. 1. RT-PCR scheme illustrating all 8 segments of FluA ampliﬁcation usingM13 tagged primers. All 6 internal primers are universal for all subtypes of seasonal human IAV,
the HA and NA primers are subtype speciﬁc. All of the forward primers are tagged with M13F universal sequencing primer at the 5′ end ( ), all the reverse primers with
M13R universal sequencing primer at the 5′ end ( ) to facilitate downstream sequencing.
4.4. Sequencing and sequence analysis of PCR products
All the PCR products generated from various subtypes were
sequenced using M13F and M13R primers. High quality sequence
datawere generatedwhichwas reﬂected by a long contiguous read
length (CRL) (up to 900bp), and a high Phred quality value (QV20+
for over 99% of the bases). The sequence data derived from both
ends using the two M13 primers effectively covered the whole
fragment for all the PCR products, alleviating the need for further
gap sequencing using additional internal primers. The assembled
sequenceswere blasted against the sequence data available inGen-
Bank. Results revealed that all the sequenced IAVs belonged to
their corresponding genes/subtypes and exhibited a high degree of
homologies to the viruses sequenced from around the same time
period.
4.5. Sequencing of IAV from original specimens
Further tests were performed to determine whether this set
of PCR primers could efﬁciently amplify IAV genes from original
specimens includingnasal swabsandnasopharyngeal aspirates col-
lected from patients. A total of 222 original specimens conﬁrmed
previously by real-time RT-PCR to carry various subtypes of IAVs
were used for HA/NA PCR and sequencing. Among them, 12 con-
tained the seasonal H1N1, 120H1N1pdm09, and 90H3N2 viruses,
with a real-time Ct value on IAV matrix gene ranging from 16 to
33. Full HA and NA genes were successfully sequenced from more
than 90% of the samples. Most of the samples that could not be
ampliﬁed for one or more fragments of HA and/or NA had a high
Ct value (>33), except for a few with a lower Ct value which most
likely contained degraded RNA. Twelve of the original specimens
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Table 1
PCR primers for full genome sequencing of human IAV.
Segment Primer name Primer sequence (5’–3’) Nucleotide positiona Expected amplicon size (bp)b Source
PB2 Fragment 1 A-PB2-I-M13F TGTAAAACGACGGCCAGTCTCGAGCAAAAGCAGGTCAA (−31)– (−20) 903 This study
A-PB2-I-M13R CAGGAAACAGCTATGACCGATGCTARTGGRTCTGCTG 836–813 This study
PB2 Fragment 2 A-PB2-II-M13F TGTAAAACGACGGCCAGTGGGARCARATGTACACTC 719–736 884 This study
A-PB2-II-M13R CAGGAAACAGCTATGACCYTGYGTTTCACTGAC 1566–1552 This study
PB2 Fragment 3 A-PB2-III-M13F TGTAAAACGACGGCCAGTGCAAAATGGGWGTRGATG 1442–1459 892 This study
A-PB2-III-M13R CAGGAAACAGCTATGACCTAGAAACAAGGTCGTT 2341–2297 This study
PB1 Fragment 1 A-PB1-I M13F TGTAAAACGACGGCCAGTAGCAAAAGCAGGCAAACCAT (−24)–(−5) 863 This study
A-PBI-I-M13R CAGGAAACAGCTATGACCTGTTCAAGCTTTTCRCAWATGC 803–782 This study
PB1 Fragment 2 A-PB1-II-M13F TGTAAAACGACGGCCAGTCRATGACCAAAGATGCWGA 677–695 978 This study
A-PB1-II-M13R CAGGAAACAGCTATGACCAAGGTCATTGTTTATCATRTTG 1618–1597 This study
PB1 Fragment 3 A-PB1-III-M13F TGTAAAACGACGGCCAGTGTGGCYAATTTYAGCATGGAG 1504–1524 833 This study
A-PB1-III-M13F CAGGAAACAGCTATGACCAGTAGAAACAAGGCATTT 2317–2300 This study
PA Fragment 1 A-PA-I-M13F TGTAAAACGACGGCCAGTAGCAAAAGCAGGTACTGAT (−24)–(−6) 1019 This study
A-PA-I-M13R CAGGAAACAGCTATGACCGGYTCTTTCCAKCCAAAG 959–942 This study
PA Fragment 2 A-PA-II-M13F TGTAAAACGACGGCCAGTCMAARTTCCTSCTGATG 839–855 798 This study
A-PA-II-M13R CAGGAAACAGCTATGACCTCMAGTCTYGGGTCAGTGAG 1600–1582 This study
PA Fragment 3 A-PA-III-M13F TGTAAAACGACGGCCAGTGCATCCTGTGCAGCMATGGA 1414–1433 836 This study
A-PA-III-M13R CAGGAAACAGCTATGACCAGTAGAAACAAGGTACCTTTT 2213–2193 This study
NP Fragment 1 A-NP-I-M13F TGTAAAACGACGGCCAGTCAGGGTWRATAATCACTCAMTG (−37)–(−16) 1053 This study
A-NP-I-M13R CAGGAAACAGCTATGACCTGRCTCTTGTGWGCTGG 980–964 This study
NP Fragment 2 A-NP-II-M13F TGTAAAACGACGGCCAGTCTGAGRGGRTCAGTTGC 795–811 762 This study
A-NP-II-M13R CAGGAAACAGCTATGACCAGTAGAAACAAGGGTATTTTTC 1520–1499 This study
M A-MP-M13F TGTAAAACGACGGCCAGTAGCAAAAGCAGGTAG (−25)–(−10) 1060 US CDC
A-MP-M13R CAGGAAACAGCTATGACCAGTAGAAACAAGGTAGT 999–986 US CDC
NS A-NS-M13F TGTAAAACGACGGCCAGTAGCAAAAGCAGGGTGACAAAGACA (−27)–(−3) 954 This study
A-NS-M13R CAGGAAACAGCTATGACCAGTAGAAACAAGGGTGTTTTTTAT 891–868 This study
sesonal H1N1
HA Fragment 1 H1-I-M13F TGTAAAACGACGGCCAGTCAACCAAAATGAAAG (−8)–7 1098 US CDC
H1-I-M13R CAGGAAACAGCTATGACCGCAATGGCTCCAAACAAACCTCT 1054–1032 US CDC
Fragment 2 H1-II-M13F TGTAAAACGACGGCCAGTAGAATYAAYTACTACTGGAC 727–746 1055 US CDC
H1-II-M13R CAGGAAACAGCTATGACCAGTAGAAACAAGGGTGTTTTTYCTYATATT 1745–1716 This study
NA Fragment 1 uNA-I-M13F TGTAAAACGACGGCCAGTAGCAAAAGCAGGAGT (−20)–(−6) 793 US CDC
N1-I-M13R CAGGAAACAGCTATGACCGGRCCATCGGTCATTATG 720–737 US CDC
Fragment 2 N1-II-M13F TGTAAAACGACGGCCAGTGGAATTTCYGGTCCAG 580–595 898 US CDC
uNA-II-M13R CAGGAAACAGCTATGACCAGTAGAAACAAGGAG 1441–1427 US CDC
pdm H1N1
HA Fragment 1 pdmHA-I-MI3F TGTAAAACGACGGCCAGTATGAAGGCAATACTAGTAG 1–19 976 This study
pdmHA-I-MI3R CAGGAAACAGCTATGACCGATCGGATGTATATTCTGAAATGG 940–922 This study
Fragment 2 pdmHA-II-MI3F TGTAAAACGACGGCCAGTGATTGCAATACAACTTGTC 871–889 890 This study
pdmHA-II-MI3R CAGGAAACAGCTATGACCTCATGCTTCTGA 1724–1712 This study
NA Fragment 1 pdmNA-I-MI3F TGTAAAACGACGGCCAGTAGCAAAAGCAGGAG (−20)–(−7) 863 This study
pdmNA-I-MI3R CAGGAAACAGCTATGACCGTGATAATTAGGGGCATTC 823–807 This study
Fragment 2 pdmNA-II-MI3F TGTAAAACGACGGCCAGTGACAGGCCTCATACAAGATCTTC 746–768 703 This study
pdmNA-II-MI3R CAGGAAACAGCTATGACCAATTACTTGTCAATGG 1412–1397 This study
H3N2
HA Fragment 1 H3-I-M13F TGTAAAACGACGGCCAGTAAAGCAGGGGATAATTCTA (−25)–(−7) 1230 This study
H3-I-M13R CAGGAAACAGCTATGACCATTGCTGCTTGAGTGCTT 1169–1152 This study
Fragment 2 H3-II-M13F TGTAAAACGACGGCCAGTGGTTACTTCAAAATAC 814–829 937 This study
H3-II-M13R CAGGAAACAGCTATGACCAGTAGAAACAAGGGTGTTTT 1733–1714 This study
NA Fragment 1 uNA-I-M13F TGTAAAACGACGGCCAGTAGCAAAAGCAGGAGT (−19)–(−5) 878 US CDC
N2-I-M13R CAGGAAACAGCTATGACCCGACATGCTGAGCACTYCCTGAC 823–804 This study
Fragment 2 N2-II-M13F TGTAAAACGACGGCCAGTGAACTTGTRCAGTRGTAATG 704–723 780 US CDC
uNA-II-M13R CAGGAAACAGCTATGACCAGTAGAAACAAGGAG 1447–1433 US CDC
a The start codon “ATG” of each gene is designated position #4′5#, some primers start before the start codon, and are given a negative number.
b The amplicon sizes include the M13F and M13R primer lengths.
(two containing H3N2 and 10H1N1pdm09) were chosen for full
genome sequencing. All 12 samples had a Ct value on IAV matrix
gene between 17 and 27. Results revealed that sequencing the full
length of all eight genes was achieved with all of the 12 original
samples.
5. Discussion
Full genome sequencing of IAV has been increasingly used for
research and global surveillance of inﬂuenza viruses. Traditionally,
this has been done by Sanger sequencing; however, the most crit-
ical determinant for a successful full genome Sanger sequencing
strategy of IAV is the availability of primers that are able to tar-
get only the IAV sequences reliably but not the sequences of host
genes or other pathogens. Due to the high diversity of IAVs, most
of the Sanger-based methods developed to date are IAV subtype
speciﬁc and often require the use of large numbers of primers. For
example, the method reported by Lee et al [27] is applicable only
to H3N2 subtype viruses, and it involves the use of 19 pairs of PCR
primers for full genome ampliﬁcation of the viruses, followed by an
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Table 2
Representatives of viruses from different subtypes of IAV being sequenced using the IAV internal primers.
Subtype Virus designation Year Isolate type Virus host GISAID Isolate ID Genes sequenced
H3N2 A/Victoria/186/1982 1982 Egg Human EPI ISL 173279 PB2,PB1,PA,NP,M,NS
A/Sydney/2/1993 1993 MDCK Human EPI ISL 173280 PB2,PB1,PA,NP,M,NS
A/Nauru/5/2011 2011 Clinical specimen Human EPI ISL 95078 PB2,PB1,PA,NP,M,NS
A/South Australia/313/2011 2011 Clinical specimen Human EPI ISL 118601 PB2,PB1,PA,NP,M,NS
A/Newcastle/1/2013 2013 MDCK Human EPI ISL 141550 PB2,PB1,PA,NP,M,NS
sH1N1 A/Queensland/1/1983 1983 Egg Human EPI ISL 173281 PB2,PB1,PA,NP,M,NS
A/Victoria/4/1986 1986 Egg Human EPI ISL 173282 PB2,PB1,PA,NP,M,NS
A/Victoria/1/1991 1991 Egg Human EPI ISL 173276 PB2,PB1,PA,NP,M,NS
A/Perth/5/1995 1995 MDCK Human EPI ISL 173283 PB2,PB1,PA,NP,M,NS
H1N1pdm09 A/Auckland/1/2009 2009 Clinical specimen Human EPI ISL 30628 PB2,PB1,PA,NP,M,NS
A/Guam/2/2010 2010 Clinical specimen Human EPI ISL 76617 PB2,PB1,PA,NP,M,NS
A/Townsville/5/2013 2013 MDCK Human EPI ISL 148750 PB2,PB1,PA,NP,M,NS
H2N2 A/Singapore/1/1957 1957 Egg Human EPI ISL 130414a PB2,PB1,PA,NP,M,NS
H1N2 A/Brisbane/116/2002 2002 MDCK Human EPI ISL 173277 PB2,PB1,PA,NP,M,NS
A/Sydney/12/2003 2003 MDCK Human EPI ISL 173278 PB2,PB1,PA,NP,M,NS
H10N7 A/Chicken/Queensland/1/2012 2012 Egg Chicken EPI ISL 129740 PB2,PB1,PA,NP,M,NS
H7N9 A/Anhui/1/2013 2013 Egg Human EPI ISL 138739a PB2,PB1,PA,NP,M,NS
H9N2 A/Hong Kong/33982/2009 2009 MDCK Human EPI ISL 69733a NP,M,NS,
H5N1 A/Turkey/15/2006 2006 MDCK Human EPI ISL 12586a NP,M,NS,
a Our sequences match the sequences previously existed in the database, with the accession numbers listed.
additional 40 primers for sequencing the PCR products. Similarly,
198 primer setswere used initially to amplify and sequence the full
genome of the ﬁrst novel avian A(H7N9) virus that arose in China
in 2013 which has now resulted in hundreds of human infections
and many deaths [10].
In this study, we demonstrated that using a set of only 13 pairs
of primers we successfully ampliﬁed and sequenced all of the six
internal gene segments frommultiple IAVsubtypes. Although these
primers were mainly designed to sequence the circulating human
IAV subtypes, they could also be used to sequence a limited number
ofother IAVsubtypes fromhumanandanimal sources. Forexample,
this set of primers successfully ampliﬁed and sequenced the full
internal genes from H2N2, H10N7 and H1N2 viruses as well as the
recently emerged avian H7N9 virus from China. Due to the high
diversity of other IAVs, however, we found it very difﬁcult, if not
impossible to design a set of primers that could universally amplify
the six internal genes from all inﬂuenza A subtypes.
In contrast to the six internal genes, the genes for HA and NA
are notorious for their high heterogeneity which makes it impos-
sible to design a set of primers that are applicable to the HA and
NA genes of all subtypes. Therefore, in this study, the HA and NA
genes of only three IAV subtypes were chosen as the targets for full
genomesequencingbecauseof their presence in thegeneral human
population in recent years. The primers designed were evaluated
extensively for their subtype speciﬁcities on over 3200 cultured
IAVs of different subtypes including H1N1, H3N2 and H1N1pdm09
viruses. The results demonstrated that the HA- and NA- speciﬁc
primers could be applied to a wide range of viruses isolated from
1934 to the present time, and that no cross-reactivity between dif-
ferent IAV subtypes or to inﬂuenza B virus was detected with any
of the primers tested. Most importantly, all the primers reported
in this study did not cross react with other pathogens or host
genes. In addition, the use of a single pair of M13 primers for
all sequencing reactions not only simpliﬁes the sequencing pro-
cedure but also ensures the generation of high quality sequences
consistently.
With our simple and streamlined full genome Sanger sequenc-
ing protocol, up to ﬁve viruses can be sequenced overnight with
just two 96-well sequencing plates on ABI 3500XL sequencer.
The sequence data can be analysed using many standard pro-
grams quickly, leading to a much shorter turnaround times than
are usually seen with NGS, especially in the case when only a
small number of viruses are sequenced. Given the sensitivity of the
primerpairs these assays couldbeusedonboth cell culture-derived
and egg-grown virus isolates, as well as on clinical respiratory
specimens when there is sufﬁcient virus present. In conclusion,
this simple Sanger sequencing protocol provides a useful backup
sequencing strategy in this current era of NGS, and also enables
smaller laboratories that do not have NGS equipment to use this
Sanger sequencing method to rapidly and reliably sequence the
circulating human IAV genomes from their regions.
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